Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

arch agreements

--500,000100,000Total revenues

156,352208,6521,480,362892,644Operating expenses:Research and development

6,940,5647,573,25132,797,67234,416,983Marketing

1,995,716194,8335,051,0061,049,760General and administrative

3,710,7392,074,19212,499,8778,024,138Total operating expenses

12,647,0199,842,27650,348,55543,490,881Loss from operations

(12,490,667)(9,633,624)(48,868,193)(42,598,237)Interest income and other, net

227,89955,025329,290363,998Consolidated net loss

$(12,262,768)$ (9,578,599)$(48,538,903)$(42,234,239)Net loss attributable to noncontrolling interest

316,766141,6821,199,161141,682 Net loss attributable to Optimer Pharmaceuticals, Inc. common stockholders

$(11,946,002)$ (9,436,917)$(47,339,742)$(42,092,557)Basic and diluted net loss per share attributable to common stockholders

$
(0.31)$
(0.28)$
(1.25)$
(1.30)Shares used to compute basic and diluted net  loss per share attributable to common stockholders

39,140,21433,117,09537,830,45232,468,702Optimer Pharmaceuticals, Inc.Consolidated Balance SheetsYear Ended December 31,20102009ASSETSCurrent assets:Cash and cash equivalents

$  19,861,924$ 17,054,328Short-term investments

29,553,50621,131,145Prepaid expenses and other current assets

516,859416,859Total current assets

49,932,28938,602,332Property and equipment, net

697,683672,896Long-term investments

882,000882,000Other assets

508,190498,762Total assets

$  52,020,162$ 40,655,990LIABILITIES  AND STOCKHOLDERS'  EQUITYCurrent liabilities:Accounts payable

$
2,307,820$   2,625,240Accrued expenses

2,385,0465,025,669Total current liabilities

$
4,692,866$   7,650,909Deferred rent

141,138253,474Commitments and contingencies

--Stockholders’ equity

47,186,15832,751,607Total liabilities and stockholders’ e
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 ... report "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT ... - I-131, Alpha Emitters, Brachytherapy - Y-90), by ... 2020", published by MarketsandMarkets, this report studies the ... of 2015 to 2020. This market is expected ...
(Date:7/7/2015)... julio de 2015 Sequent Medical, una ... en el desarrollo de dispositivos innovadores para el ... que R. Michael Kleine se ha ... Kleine cuenta con más de 25 años de ... y la sanidad. Ha gestionado con éxito varias ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "The New Trends of ... their offering. The report, The New ... unique insights into the current development states and ... development outsourcing market. The report is designed to ...
Breaking Medicine Technology:Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 2Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 3Nuclear Medicine/Radiopharmaceuticals Market Worth $6.96 Billion by 2020 4Sequent Medical nombra a Mike Kleine a su junta directiva 2Sequent Medical nombra a Mike Kleine a su junta directiva 3New Trends in the 2015 Global Preclinical Development Outsourcing Market 2New Trends in the 2015 Global Preclinical Development Outsourcing Market 3New Trends in the 2015 Global Preclinical Development Outsourcing Market 4New Trends in the 2015 Global Preclinical Development Outsourcing Market 5
... LAKE SUCCESS, N.Y., Sept. 7, 2011 As NFL coaches ... strength and conditioning programs, one team,s preparation will be gaining ... during the 2011 NFL season. Today, Polar USA and the ... has been designated the "Official Heart Rate Training System" of ...
... 7, 2011 Cyberonics, Inc. (NASDAQ: CYBX ), ... participate in the 2011 UBS Global Life Sciences Conference on ... Moore, Cyberonics, President and Chief Executive Officer, will speak to ... live audio webcast of the presentation can be accessed by ...
Cached Medicine Technology:Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 3
(Date:7/7/2015)... Irvine, CA (PRWEB) , ... July 07, 2015 ... ... outlined a report from Cambridge Consultants that discussed how innovation and technology ... The article outlined the need to address issues of accessibility and affordability, especially ...
(Date:7/7/2015)... ... ... Silverado today issues its first update on construction of a new memory care ... in Bellingham, Washington. Cordata Design Review Board approved design and landscape plans for the ... local community. , The new complex – located at the 4400 block of Cordata ...
(Date:7/7/2015)... , ... July 07, 2015 ... ... convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, ... program, surpassing their original 2015 fundraising goal by nearly $100,000, to help ...
(Date:7/7/2015)... ... July 07, 2015 , ... A June ... rejuvenation that have emerged about Hillary Clinton. Two plastic surgeons consulted by the ... youthful than she has in some time and speculate that she might have ...
(Date:7/7/2015)... ... ... Quadrino Law Group is pleased to announce the relocation of the firm's headquarters to ... is a state of the art building, located with easy access to New York ... said, "We are pleased to service our clients from such a premier location and ...
Breaking Medicine News(10 mins):Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 2Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 3Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3
... is also available in Chinese on EurekAlert! ... and pain some people experience while using in-ear headphones, hearing ... external sound -- have found not only what they believe ... separate papers and a presentation at the 130th Audio Engineering ...
... In a time of transition for rural African-American ... stay focused on their goals and avoid potential difficulties ... ongoing University of Georgia study., The study, published in ... Community Psychology, is part of a broader research ...
... routine medical exam, Charles Harris learned that he had incurable ... keep family and friends current on his progress, and found ... book Incurable, an account of a man,s struggle to live ... illness. An entrepreneur and investor by profession, Charles Harris ...
... -- Use of the illegal drug ecstasy is associated with ... U.S. researchers used functional MRI to compare the brain,s response ... had used ecstasy, though not within two weeks of the ... Ecstasy users with the highest lifetime exposure to the drug ...
... Japanese and U.S. scientists in the young field of epigenetics ... silenced and others are not. Because this effect can be ... and other diseases using this information. The NOVA ... In Your Genes." It is the study of changes in ...
... 2011 Each year during National Nurses Week, UC ... patient care, education and guidance, mentorship, and teamwork. ... care," said Karen Grimley, chief nursing officer at UC ... noted that the approximately 1,200 nurses there are caring ...
Cached Medicine News:Health News:Sound safety 2Health News:Sound safety 3Health News:Sound safety 4Health News:Sound safety 5Health News:Study finds youth-mentor relationships particularly helpful for those experiencing hardship 2Health News:Ecstasy Use May Make Brain Less Efficient 2Health News:Study gives clue as to how notes are played on the genetic piano 2
... Size: 4.0 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
... 80 mm. Half oval. The original Scleral Sponge ... has been modified by Dr. Joseph Olk with ... closed cell sponge which is non-toxic and non-antigenic. ... scleral intrusion. These implants are packaged sterile and ...
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
For use with E5381 600 Circling Band (40 style)....
Medicine Products: